Cancer Research Cancer Medicine 8  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shukeir, N.
Right arrow Articles by Rabbani, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shukeir, N.
Right arrow Articles by Rabbani, S. A.
[Cancer Research 66, 9202-9210, September 15, 2006]
© 2006 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo

Nicholas Shukeir1,2, Pouya Pakneshan1,2, Gaoping Chen1,2, Moshe Szyf1,3 and Shafaat A. Rabbani1,2

Departments of 1 Medicine, 2 Oncology, and 3 Pharmacology, McGill University, Montreal, Quebec, Canada

Requests for reprints: Shafaat A. Rabbani, McGill University Health Centre, 687 Pine Avenue West, Room H4-68, Montreal, Quebec, Canada H3A 1A1. Phone: 514-843-1632; Fax: 514-843-1712; E-mail: shafaat.rabbani{at}mcgill.ca.

We tested the hypothesis that cell invasiveness and tumorigenesis are driven by hypomethylation of genes involved in tumor progression. Highly invasive human prostate cancer cells PC-3 were treated with either the methyl donor S-adenosylmethionine (SAM) or methyl DNA-binding domain protein 2 antisense oligonucleotide (MBD2-AS). Both treatments resulted in a dose- and time-dependent inhibition of key genes, such as urokinase-type plasminogen activator (uPA), matrix metalloproteinase-2 (MMP-2), and vascular endothelial growth factor expression to decrease tumor cell invasion in vitro. No change in the levels of expression of genes already known to be methylated in late-stage prostate cancer cells, such as glutathione S-transferase P1 and androgen receptor, was seen. Inoculation of PC-3 cells pretreated with SAM and MBD2-AS into the flank of male BALB/c nu/nu mice resulted in the development of tumors of significantly smaller volume compared with animals inoculated with PC-3 cells treated with vehicle alone or MBD2 scrambled oligonucleotide. Immunohistochemical analysis of tumors showed the ability of SAM and MBD2-AS to significantly decrease tumoral uPA and MMP-2 expression along with levels of angiogenesis and survival pathway signaling molecules. Bisulfite sequencing analysis of tumoral genomic DNA showed that inhibition of both uPA and MMP-2 expression was due to methylation of their 5' regulatory region. These studies support the hypothesis that DNA hypomethylation controls the activation of multiple tumor-promoting genes and provide valuable insight into developing novel therapeutic strategies against this common disease, which target the demethylation machinery. (Cancer Res 2006; 66(18): 9202-10)




This article has been cited by other articles:


Home page
International Journal of ToxicologyHome page
D. Desaulniers, G.-h. Xiao, H. Lian, Y.-L. Feng, J. Zhu, J. Nakai, and W. J. Bowers
Effects of Mixtures of Polychlorinated Biphenyls, Methylmercury, and Organochlorine Pesticides on Hepatic DNA Methylation in Prepubertal Female Sprague-Dawley Rats
International Journal of Toxicology, July 1, 2009; 28(4): 294 - 307.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Hervouet, E. Debien, L. Campion, J. Charbord, J. Menanteau, F. M. Vallette, and P.-F. Cartron
Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation
Clin. Cancer Res., May 15, 2009; 15(10): 3519 - 3529.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. J. Jun, S. Woolfenden, S. Coven, K. Lane, R. Bronson, D. Housman, and A. Charest
Epigenetic Regulation of c-ROS Receptor Tyrosine Kinase Expression in Malignant Gliomas
Cancer Res., March 15, 2009; 69(6): 2180 - 2184.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Zhang and I. Pastan
High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy
Clin. Cancer Res., December 15, 2008; 14(24): 7981 - 7986.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. B. Lokeshwar, P. Gomez, M. Kramer, J. Knapp, M. A. McCornack, L. E. Lopez, N. Fregien, N. Dhir, S. Scherer, D. J. Klumpp, et al.
Epigenetic Regulation of HYAL-1 Hyaluronidase Expression: IDENTIFICATION OF HYAL-1 PROMOTER
J. Biol. Chem., October 24, 2008; 283(43): 29215 - 29227.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Szyf
The Dynamic Epigenome and its Implications in Toxicology
Toxicol. Sci., November 1, 2007; 100(1): 7 - 23.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.